Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Alexion Pharmaceuticals, Inc.    ALXN

ALEXION PHARMACEUTICALS, INC.

(ALXN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/15/2021 01/19/2021 01/20/2021 01/21/2021 01/22/2021 Date
156.7(c) 158.71(c) 157.74(c) 157.86(c) 159.73(c) Last
2 106 122 4 397 079 3 717 827 3 579 909 2 789 197 Volume
+0.03% +1.28% -0.61% +0.08% +1.18% Change
More quotes
Financials (USD)
Sales 2020 5 980 M - -
Net income 2020 516 M - -
Net cash position 2020 808 M - -
P/E ratio 2020 68,7x
Yield 2020 -
Sales 2021 6 537 M - -
Net income 2021 2 430 M - -
Net cash position 2021 1 958 M - -
P/E ratio 2021 14,4x
Yield 2021 -
Capitalization 34 956 M 34 956 M -
EV / Sales 2020 5,71x
EV / Sales 2021 5,05x
Nbr of Employees 3 082
Free-Float 91,1%
More Financials
Company
Alexion Pharmaceuticals, Inc. specializes in the research and development of therapeutic products used in treating hematological and cardiovascular diseases, auto-immune diseases, and cancers. At the end of 2019, the group had a portfolio of 6 products in clinical development. Net sales are distributed geographically as follows: the United States (55.6%), Europe (24.2%), Asia/Pacific (10.6%) and other (9.6%). 
More about the company
Notations Surperformance© of Alexion Pharmaceuticals, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about ALEXION PHARMACEUTICALS, INC.
01/22PRESS RELEASE : BB BIOTECH AG: Vaccines leading -2-
DJ
01/13ALEXION PHARMACEUTICALS : pauses enrollment for COVID-19 study testing its rare ..
RE
01/13ALEXION PHARMACEUTICALS : Independent Panel Recommends Enrollment Cessation for ..
MT
01/13ALEXION PHARMACEUTICALS : pauses enrollment for COVID-19 study testing its rare ..
RE
01/13ALEXION PHARMACEUTICALS : Provides Update on Phase 3 Study of ULTOMIRIS® (ravuli..
BU
01/12ALEXION PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, R..
AQ
01/12ALEXION PHARMACEUTICALS :  Alexion Highlights Commercial, Clinical and Financial..
BU
01/08ALEXION PHARMACEUTICALS : Raymond James Downgrades Alexion Pharmaceuticals to Ma..
MT
01/05ALEXION PHARMACEUTICALS : to Present at the 39th Annual J.P. Morgan Healthcare C..
BU
01/05ALEXION PHARMACEUTICALS : Stifel Adjusts Alexion Pharmaceuticals' Price Target t..
MT
2020MARKET CHATTER : Dealmaking Worldwide Reportedly Falls to Three-Year Low in Year..
MT
2020ALEXION PHARMACEUTICALS : Fewer companies caught the deal bug in the year of the..
RE
2020Moderna Receives Price-Target Increase as Oppenheimer Sees COVID-19 Vaccine P..
MT
2020SHAREHOLDER ALERT : Monteverde & Associates PC Announces an Investigation of Ale..
PR
2020MODERNA, EXXON, ALPHABET, AMAZON : Stocks That Defined the Week
DJ
More news
News in other languages on ALEXION PHARMACEUTICALS, INC.
2020MÄRKTE USA/Hoffnung auf Konjunkturpaket beflügelt Wall Street
2020MÄRKTE USA/Hoffnung auf Konjunkturpaket hievt Wall Street ins Plus
2020MÄRKTE USA/Hoffnungen auf Konjunkturpaket sorgen für Plus
2020MÄRKTE USA/Hoffnungen auf Konjunkturpaket dürften für Plus sorgen
2020WALL STREET STOCK EXCHANGE : S&P 500 cae en jornada de despliegue de vacuna y de..
More news
Analyst Recommendations on ALEXION PHARMACEUTICALS, INC.
More recommendations
Chart ALEXION PHARMACEUTICALS, INC.
Duration : Period :
Alexion Pharmaceuticals, Inc. Technical Analysis Chart | ALXN | US0153511094 | MarketScreener
Technical analysis trends ALEXION PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 19
Average target price 177,00 $
Last Close Price 159,73 $
Spread / Highest target 25,2%
Spread / Average Target 10,8%
Spread / Lowest Target 3,30%
EPS Revisions
Managers and Directors
NameTitle
Ludwig N. Hantson Chief Executive Officer & Director
Aradhana Sarin President & Director
David Richard Brennan Chairman
Brian M. Goff Chief Commercial, Global Operations Officer & EVP
John J. Orloff Executive VP, Head-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ALEXION PHARMACEUTICALS, INC.1.04%34 956
CSL LIMITED-3.03%96 409
SAMSUNG BIOLOGICS CO.,LTD.-3.87%47 496
BIOGEN INC.10.04%41 462
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD.10.88%40 484
UCB3.67%20 143